Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
← catalyst calendarNCT05834296 · readout in 561 d
Sponsored by Alzamend Neuro, Inc. (industry) · ALZN — their whole pipeline →. With bioRASI, LLC.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
30estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-05 | actual | When the study began enrolling |
| Primary completion | 2028-03-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-03 | estimated | The whole study's end, after follow-up |
| First posted | 2023-04-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimer Disease
Interventions
- Biological: ALZN002 (autologous DCs pulsed with E22W mutant peptide).
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTEAEs
measured Through study completion, up to 33 months
Permalink · ALZN's whole pipeline · Catalyst calendar · Every registered study · What changed